Alar Pharmaceuticals (ROCO:6785) Moat Score: 0/10 (As of Jul. 13, 2026)


ROCO:6785 Alar Pharmaceuticals Inc ROCO:6785
52 GF Score
Price NT$117.00
GF Value NT$90.64
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Alar Pharmaceuticals Moat Score?

Alar Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Alar Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Alar Pharmaceuticals might have No Moat - No discernible moat.

Alar Pharmaceuticals  (ROCO:6785) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Alar Pharmaceuticals Moat Score Related Terms

ROCO:6785
52GF Score
Alar Pharmaceuticals Inc ROCO:6785
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alar Pharmaceuticals (ROCO:6785) Overvalued in 2026?

Based on GuruFocus' analysis, Alar Pharmaceuticals stock appears to be overvalued. The current stock price of NT$117.00 is trading 29.1% above its estimated GF Value™ of NT$90.64. GuruFocus considers Alar Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for ROCO:6785:

  • Moat Score: 0
  • GF Value™: NT$90.64 vs. price of NT$117.00 (29.1% above fair value)
  • GF Score™: 52/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6785 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alar Pharmaceuticals Business Description

Address Jhongke Road, No. 32, No. 2, 5th Floor, Situn District, Taichung, TWN, 428015
Alar Pharmaceuticals Inc is a drug development company mainly engaged in the research and development of new drugs, sales of western pharmaceuticals, and medical devices. It focuses on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and depressive disorder. The company currently has only a new drug development division, and its product pipeline comprises various drug candidates such as ALA-1000 (Buprenorphine), ALA-1300, ALA-2000 (Naltrexone), ALA-3000 (Ketamine), ALA-4000 (Apomorphine), and ALA-5000 (Third-generation antipsychotic). Geographically, the company generates maximum revenue from the USA and also has its presence in Taiwan and the United Kingdom.
52GF Score

Get the complete analysis for ROCO:6785

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$117.00
Price
NT$90.64
GF Value